Clinical Trials
572 trialsA Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
DOTA-STR-17126
Integrated Haematology and Oncology Network
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Alterome Therapeutics, Inc.
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
GlaxoSmithKline
PIKALO-1
Eli Lilly and Company
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
Immunome, Inc.
Real-Time IGRT
University of Sydney
Cancer
Federal University of Maranhao
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
AstraZeneca
FOCUS
Ohio State University Comprehensive Cancer Center
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.
New Phase Ltd.
ULTIMO
Cancer Research Antwerp
Adaptive Symptom Self-Management Immunotherapy Study
University of Arizona
OP-NEU-101
Onchilles Pharma Inc
Dance Intervention in Breast Cancer Treatment
Federal University of Maranhao
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Cancer Research UK
Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
Vanderbilt-Ingram Cancer Center
Repeat Breast Conserving Surgery Followed by Daily Partial Breast Irradiation in Ipsilateral Breast
Case Comprehensive Cancer Center
I-SPY
QuantumLeap Healthcare Collaborative
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic Testing
Unity Health Toronto
AxeCan
HealthPartners Institute
Study of LP-184 in Patients With Advanced Solid Tumors
Lantern Pharma Inc.
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Rondo Therapeutics
Shorter Course Radiation for the Treatment of Breast Cancer That Has Spread to Lymph Nodes
University of Colorado, Denver
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Stanford University
CHEMOVES
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
NAVIGATE
Bayer
IMPACT-
Istituto di Studi Superiori Musicali (ISSM) Conservatorio Antonio Vivaldi di Alessandria
HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases
City of Hope Medical Center
ADIE-BC
King's College London
SERENA-6
AstraZeneca
AI-ChemoApp
University of Baghdad
LIBRETTO-001
Eli Lilly and Company
ROSY-O
AstraZeneca
AH-HA
Wake Forest University Health Sciences
ReRT
The New York Proton Center
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Iambic Therapeutics, Inc
BRIA-ABC
BriaCell Therapeutics Corporation
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Conjupro Biotherapeutics, Inc.
ELECTRA
Stemline Therapeutics, Inc.
A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha
Epsilogen Ltd
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
SURGE
Colorado State University
Behavioral Pain Intervention for Older Cancer Patients
Duke University
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio, Inc
MK-4700-001
Merck Sharp & Dohme LLC
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai Inc.